Our findings validate thalamic CaV3.1 T-channels as a potential new target for the development or treatment of different psychiatric diseases, such as post-traumatic stress disorder, schizophrenia, anxiety, and substance abuse disorders. This evidence concerns the gene CACNA1G and schizophrenia.